Ono Pharma’s endocannabinoid modulator flunks five trials: The biotech’s ONO-1110 did not …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Outpace ends an ovarian cancer trial; Incyte data impresses at ESMO October 27, 2026
Aspen and Bambusa target $135M IPOs; AstraZeneca vs. Takeda in gastric cancer ADCs October 26, 2026
One-person biotechs and an 'age of miracles': Anthropic reveals next leg of its biopharma vision
Updated: Lilly beats revenue forecasts, lifting full-year outlook for third straight quarter
Exclusive: Dren Bio nabs $350M for potential 2027 launch of blood cancer drug
Source link







